IP Library › Granted Patent US 12,215,097
Granted Patent B2
US 12,215,097 · App. 18/416,455 · Granted Feb 4, 2025

Derivatives of substituted morpholines and uses thereof

Inventor: Janak Khimchand Padia (Germantown, MD)
Assignee: Supernus Pharmaceuticals, Inc.
C07D413/12C07D265/30C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,097
App. No.
18/416,455
Granted
Feb 4, 2025
Kind
B2
Abstract

A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R 1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:

Claims (28)

1. A stereoisomer of a compound of the formula:

or a salt thereof.

2. The stereoisomer of claim 1 having the structure:

3. The stereoisomer of claim 1 having the structure:

4. The stereoisomer of claim 1 having the structure:

5. The stereoisomer of claim 1 having the structure:

6. The stereoisomer of claim 1 having the structure:

7. The stereoisomer of claim 1 having the structure:

8. The stereoisomer of claim 1 having the structure:

9. The stereoisomer of claim 1 having the structure:

10. The stereoisomer of claim 1 having the structure:

11. The stereoisomer of claim 1 having the structure:

12. The stereoisomer of claim 1 having the structure:

13. The stereoisomer of claim 1 having the structure:

14. The stereoisomer of claim 1 having the structure:

15. The stereoisomer of claim 1 having the structure:

16. The stereoisomer of claim 1 having the structure:

17. The stereoisomer of claim 1 having the structure:

18. The stereoisomer of claim 1 having the structure:

19. The stereoisomer of claim 1 having the structure:

20. The stereoisomer of claim 1 having the structure:

21. The stereoisomer of claim 1 having the structure:

22. The stereoisomer of claim 1 having the structure:

23. The stereoisomer of claim 1 having the structure:

24. The stereoisomer of claim 1 having the structure:

25. The stereoisomer of claim 1 having the structure:

26. The stereoisomer of claim 1 having the structure:

27. The stereoisomer of claim 1 having the structure:

Continuity (3)
Continuation 17698592 · Mar 18, 2022
Provisional Application 63162671 · Mar 18, 2021
Related Publication 20240182458A1 · Jun 6, 2024
References Cited (29)
US 3712890A · Lee · 1973 [cited by applicant]
US 11634415B2 · Padia · 2023 [cited by applicant]
US 11919889B2 · Padia · 2024 [cited by examiner]
US 20090325956A1 · Taniguchi et al. · 2009 [cited by applicant]
US 20110251198A1 · Liang et al. · 2011 [cited by applicant]
US 20230295100A1 · Sun · 2023 [cited by examiner]
US 20230357173A1 · Sun · 2023 [cited by examiner]
EP 2558437A2 · 2013 [cited by applicant]
GB 1243991A · 1971 [cited by applicant]
GB 1260886A · 1972 [cited by applicant]
GB 1310236 · 1973 [cited by applicant]
WO WO9822110A1 · 1998 [cited by applicant]
Boot et al., “Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors,” Bioorganic & Medicinal Chemistry Letters, Feb. 1, 2005, 15(3):699-70… [cited by applicant]
Brenner et al., “Asymmetric Synthesis of (+)-(S,S)-Reboxetine via a New (S)-2-(Hydroxymethyl)morpholine Preparation,” Organic Letters, Jan. 25, 2005, 7(5):937-939. [cited by applicant]
Chemical Abstracts STN Registry Database, Record for RN 1706456-61-2, “2-[(2-Methoxyphenoxy)methyl]-4-morpholineacetamide,” Entered STN May 17, 2015. [cited by applicant]
Chemical Abstracts STN Registry Database, Record for RN 921185-45-7, “2-Chloro-1-[2-[(2-methoxyphenoxy)methyl]-4-morpholinyl]ethenone,” Entered STN Feb. 15, 2017. [cited by applicant]
Fish et al., “Design and synthesis of morpholine derivatives. SAR for dual serotonin & nonadrenaline reuptake inhibition,” Bioorganic & Medicinal Chemistry Letters, 2008, 18:2562-2566. [cited by applicant]
Fish et al., “Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs,” Tetrahedron Letters, Jan. 28, 200… [cited by applicant]
International Search Report and Written Opinion dated Sep. 22, 2022 in PCT/US2022/020976. [cited by applicant]
Invitation to Pay Additional Fees and Partial International Search Report dated Jun. 27, 2022 in PCT PCT/US2022/020976. [cited by applicant]
Jobson et al., “Stereoselective synthesis of (2S,3R)- and (2R,3S)-iodoreboxetine; potential SPECT imaging agents for the nonadrenaline transporter,” Organic & Biomolecular Chemistry, 2008, 6(13):2369-2376. [cited by applicant]
Letavic et al., “2-Aryloxymethylmorpholine histamine H″3 antagonists,” Bioorganic & Medicinal Chemistry Letters, Nov. 1, 2008, 18(21):5796-5799. [cited by applicant]
Melloni et al., “Potential antidepressant agents. Alpha-Aryloxy-benzyl derivatives of ethanolamine and morpholine,” Eur. J. Med. Chem.—Chim. Ther., 1984, 19(3):235-242. [cited by applicant]
Metro et al., “Syntheses of (S,S)-Reboxetine via a Catalytic Stereospecific Rearrangement of Beta-Amino Alcohols,” The Journal of Organic Chemistry, Dec. 20, 2007, 73(2):707-710. [cited by applicant]
Yu et al., “Metabolism and in vitro drug-drug interaction assessment of viloxazine,” Xenobiotica, Jun. 10, 2020, 50(11):1285-1300. [cited by applicant]
Muro et al., “Syntheses and Pharmacological Activities of 2-(Substituted Phenoxymethyl)morpholine Derivatives,” Yakagaku Zasshi, 1986, 106(9):764-774, with English translation. [cited by applicant]
Nasser et al., “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302): Efficacy and Safety of Extended-Release Viloxazine in Adolescents with ADHD,” CNS Spectrums, Apr. 24, 2020, 25(2), Abstract 111, p. 2… [cited by applicant]
Simplicio et al., “Prodrugs for Amines,” Molecules, 2008, 13:519-547. [cited by applicant]
Burgos et al., “Prodrugs, selected examples from the Spanish market I. Carrier-linked prodrugs,” An. Quim., 2019, 115(3):209-217. [cited by applicant]